I need it for journal club presentation nephro trainee level

Created using ChatSlide

This study explores the use of Belimumab and Rituximab in treating severe lupus (SLE) cases. It examines the combination therapy's effectiveness, safety, and impact in refractory SLE through a Phase 2 double-blind trial. The findings reveal reduced anti-dsDNA antibodies, fewer severe flares, and promising safety profiles. Conclusions emphasize Belimumab's efficacy after Rituximab and its potential influence on SLE treatment protocols. Acknowledgments highlight funding sources and...